Last checked at 3 Nov 2015 07:00
3 November 2015
OptiBiotix Health plc
("OptiBiotix" or "the Company")
New patent filings
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the filing of two new patents covering its cholesterol reducing product. This increases the number of patents from nine to eleven.
The new patents reflect:-
· The success of its human studies designed to establish safety and efficacy on its capsular food supplement to reduce cholesterol
· The success of manufacturing studies designed to identify maximum production yields and volumes on its cholesterol reducing strain
· The identification of additional health benefits (hypertension reduction) shown by its cholesterol reducing strain
The Company believes that filing these patents adds a further layer of protection to its intellectual property portfolio, creates valuable assets, and increases the number of product opportunities.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the filing of these patents which add a further level of protection and value to our cholesterol reducing product. We believe these patents will further enhance the value proposition and negotiating position with commercial partners and make a significant contribution to building a successful and sustainable business for shareholders."
For further information, please contact:
OptiBiotix Health plc | www.optibiotix.com |
Stephen O'Hara, Chief Executive | Contact via Walbrook below |
Cairn Financial Advisers LLP | Tel: 020 7148 7900 |
Liam Murray | |
Avi Robinson | |
Hybridan LLP (Joint Broker) | Tel: 020 3764 2341 |
Claire Louise Noyce | |
Peterhouse Corporate Finance Ltd (Joint Broker) | Tel: 020 7469 0936 |
Lucy Williams | |
Duncan Vasey | |
Walbrook PR Ltd | Tel: 020 7933 8780 or optibiotix@walbrookpr.com |
Anna Dunphy | Mob: 07876 741 001 |
Mike Wort | Mob: 07900 608 002 |
About OptiBiotix Health PLC - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.